Biomedicines (Oct 2023)

From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients

  • Benedicte Grebstad Tune,
  • Heena Sareen,
  • Branka Powter,
  • Smadar Kahana-Edwin,
  • Adam Cooper,
  • Eng-Siew Koh,
  • Cheok S. Lee,
  • Joseph W. Po,
  • Geoff McCowage,
  • Mark Dexter,
  • Lucy Cain,
  • Geraldine O’Neill,
  • Victoria Prior,
  • Jonathan Karpelowsky,
  • Maria Tsoli,
  • Lars O. Baumbusch,
  • David Ziegler,
  • Tara L. Roberts,
  • Paul DeSouza,
  • Therese M. Becker,
  • Yafeng Ma

DOI
https://doi.org/10.3390/biomedicines11112907
Journal volume & issue
Vol. 11, no. 11
p. 2907

Abstract

Read online

Genetic histone variants have been implicated in cancer development and progression. Mutations affecting the histone 3 (H3) family, H3.1 (encoded by HIST1H3B and HIST1H3C) and H3.3 (encoded by H3F3A), are mainly associated with pediatric brain cancers. While considered poor prognostic brain cancer biomarkers in children, more recent studies have reported H3 alterations in adult brain cancer as well. Here, we established reliable droplet digital PCR based assays to detect three histone mutations (H3.3-K27M, H3.3-G34R, and H3.1-K27M) primarily linked to childhood brain cancer. We demonstrate the utility of our assays for sensitively detecting these mutations in cell-free DNA released from cultured diffuse intrinsic pontine glioma (DIPG) cells and in the cerebral spinal fluid of a pediatric patient with DIPG. We further screened tumor tissue DNA from 89 adult patients with glioma and 1 with diffuse hemispheric glioma from Southwestern Sydney, Australia, an ethnically diverse region, for these three mutations. No histone mutations were detected in adult glioma tissue, while H3.3-G34R presence was confirmed in the diffuse hemispheric glioma patient.

Keywords